Clinical Trials Update

MELBOURNE,31March2022: Anatara Lifesciences (ASX: ANRor “the Company”), a developer of evidence-based solutions for gastrointestinal diseasesis pleased toprovide an update on progress of clinical trials in psychological functioning and irritable bowel syndrome, diarrhoea subtype (IBS-D). • Continuingrecruitment for two human clinical trials with ethics approval o GaRP in Irritable Bowel Syndrome–d